125 related articles for article (PubMed ID: 38513163)
21. GALAD outperforms aMAP and ALBI for predicting HCC in patients with compensated advanced chronic liver disease: A 12-year prospective study.
Villa E; Donghia R; Baldaccini V; Tedesco CC; Shahini E; Cozzolongo R; Ascari S; Pesole PL; Coletta S; Critelli RM; Lasagni S; Schepis F; Semellini F; Giannelli G
Hepatol Commun; 2023 Oct; 7(10):. PubMed ID: 37708455
[TBL] [Abstract][Full Text] [Related]
22. Utility of serological tumor biomarkers for surveillance of hepatocellular carcinoma in patients undergoing dialysis.
Toyoda H; Kikuchi K; Tsuruta Y; Hiraoka A; Tsuji K; Tanaka J
Nephrol Dial Transplant; 2021 May; 36(6):1097-1103. PubMed ID: 33009910
[TBL] [Abstract][Full Text] [Related]
23. Validation of the GALAD Model and Establishment of GAAP Model for Diagnosis of Hepatocellular Carcinoma in Chinese Patients.
Liu M; Wu R; Liu X; Xu H; Chi X; Wang X; Zhan M; Wang B; Peng F; Gao X; Shi Y; Wen X; Ji Y; Jin Q; Niu J
J Hepatocell Carcinoma; 2020; 7():219-232. PubMed ID: 33123501
[TBL] [Abstract][Full Text] [Related]
24. Updating the Clinical Application of Blood Biomarkers and Their Algorithms in the Diagnosis and Surveillance of Hepatocellular Carcinoma: A Critical Review.
Shahini E; Pasculli G; Solimando AG; Tiribelli C; Cozzolongo R; Giannelli G
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901717
[TBL] [Abstract][Full Text] [Related]
25. GALAD Score Detects Early-Stage Hepatocellular Carcinoma in a European Cohort of Chronic Hepatitis B and C Patients.
Schotten C; Ostertag B; Sowa JP; Manka P; Bechmann LP; Hilgard G; Marquardt C; Wichert M; Toyoda H; Lange CM; Canbay A; Johnson P; Wedemeyer H; Best J
Pharmaceuticals (Basel); 2021 Jul; 14(8):. PubMed ID: 34451832
[TBL] [Abstract][Full Text] [Related]
26. The GALAD score and the BALAD-2 score correlate with transarterial and systemic treatment response and survival in patients with hepatocellular carcinoma.
Olbrich A; Niemeyer J; Seiffert H; Ebel S; Gros O; Lordick F; Forstmeyer D; Seehofer D; Rademacher S; Denecke T; Matz-Soja M; Berg T; van Bömmel F
J Cancer Res Clin Oncol; 2024 Feb; 150(2):81. PubMed ID: 38319485
[TBL] [Abstract][Full Text] [Related]
27. Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case-Control Study.
Piratvisuth T; Tanwandee T; Thongsawat S; Sukeepaisarnjaroen W; Esteban JI; Bes M; Köhler B; He Y; Swiatek-de Lange M; Morgenstern D; Chan HL
Hepatol Commun; 2022 Apr; 6(4):679-691. PubMed ID: 34796691
[TBL] [Abstract][Full Text] [Related]
28. Validation of a Novel Multitarget Blood Test Shows High Sensitivity to Detect Early Stage Hepatocellular Carcinoma.
Chalasani NP; Porter K; Bhattacharya A; Book AJ; Neis BM; Xiong KM; Ramasubramanian TS; Edwards DK; Chen I; Johnson S; Roberts LR; Kisiel JB; Reddy KR; Singal AG; Olson MC; Bruinsma JJ
Clin Gastroenterol Hepatol; 2022 Jan; 20(1):173-182.e7. PubMed ID: 34391922
[TBL] [Abstract][Full Text] [Related]
29. Performance of GALAD score and serum biomarkers for detecting NAFLD-related HCC: a systematic review and network meta-analysis.
Li H; Liu H; Yan LJ; Ding ZN; Zhang X; Pan GQ; Han CL; Tian BW; Tan SY; Dong ZR; Wang DX; Yan YC; Li T
Expert Rev Gastroenterol Hepatol; 2023; 17(11):1159-1167. PubMed ID: 37929312
[TBL] [Abstract][Full Text] [Related]
30. HES V2.0 outperforms GALAD for detection of HCC: A phase 3 biomarker study in the United States.
El-Serag HB; Jin Q; Nabihah T; Salem E; Luster M; Alsarraj A; Khaderi S; Singal AG; Marrero JA; Asrani SK; Kanwal F
Hepatology; 2024 Jun; ():. PubMed ID: 38899967
[TBL] [Abstract][Full Text] [Related]
31. Diagnosis of hepatocellular carcinoma based on salivary protein glycopatterns and machine learning algorithms.
Tang Z; Zhang F; Wang Y; Zhang C; Li X; Yin M; Shu J; Yu H; Liu X; Guo Y; Li Z
Clin Chem Lab Med; 2022 Nov; 60(12):1963-1973. PubMed ID: 36113983
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of GALAD Score in Diagnosis and Follow-up of Hepatocellular Carcinoma after Local Ablative Therapy.
Eletreby R; Elsharkawy M; Taha AA; Hassany M; Abdelazeem A; El-Kassas M; Soliman A
J Clin Transl Hepatol; 2023 Apr; 11(2):334-340. PubMed ID: 36643039
[TBL] [Abstract][Full Text] [Related]
33. Refinement and validation of a comprehensive clinical diagnostic model (GAMAD) based on gender, age, multitarget circulating tumour DNA methylation signature and commonly used serological biomarkers for early detection of hepatocellular carcinoma: a multicentre, prospective observational study protocol.
Yang T; Wang N; Wang F; Liu H; Shen F; Lv G
BMJ Open; 2023 Sep; 13(9):e076467. PubMed ID: 37723113
[TBL] [Abstract][Full Text] [Related]
34. A Statistical Approach to the Diagnosis and Prediction of HCC Using CK19 and Glypican 3 Biomarkers.
Burciu C; Șirli R; Bende R; Popa A; Vuletici D; Miuțescu B; Rațiu I; Popescu A; Sporea I; Dănilă M
Diagnostics (Basel); 2023 Mar; 13(7):. PubMed ID: 37046471
[TBL] [Abstract][Full Text] [Related]
35. Does Hepatocellular Carcinoma Surveillance Increase Survival in At-Risk Populations? Patient Selection, Biomarkers, and Barriers.
Deng LX; Mehta N
Dig Dis Sci; 2020 Dec; 65(12):3456-3462. PubMed ID: 32860090
[TBL] [Abstract][Full Text] [Related]
36. Circulating DNA methylation profile improves the accuracy of serum biomarkers for the detection of nonmetastatic hepatocellular carcinoma.
Phan TH; Chi Nguyen VT; Thi Pham TT; Nguyen VC; Ho TD; Quynh Pham TM; Tran TH; Nguyen TD; Khang Le ND; Nguyen TH; Duong ML; Bach HT; Kim VV; Pham TA; Nguyen BT; Vo Nguyen TN; Nguyen TD; Bieu Phu DT; Huu Phan BH; Nguyen DS; Truong DK; Do TT; Giang H; Nguyen HN; Phan MD; Tran LS
Future Oncol; 2022 Dec; 18(39):4399-4413. PubMed ID: 36786635
[TBL] [Abstract][Full Text] [Related]
37. Novel, high accuracy models for hepatocellular carcinoma prediction based on longitudinal data and cell-free DNA signatures.
Fan R; Chen L; Zhao S; Yang H; Li Z; Qian Y; Ma H; Liu X; Wang C; Liang X; Bai J; Xie J; Fan X; Xie Q; Hao X; Wang C; Yang S; Gao Y; Bai H; Dou X; Liu J; Wu L; Jiang G; Xia Q; Zheng D; Rao H; Xia J; Shang J; Gao P; Xie D; Yu Y; Yang Y; Gao H; Liu Y; Sun A; Jiang Y; Yu Y; Niu J; Sun J; Wang H; Hou J
J Hepatol; 2023 Oct; 79(4):933-944. PubMed ID: 37302583
[TBL] [Abstract][Full Text] [Related]
38. Using Quasispecies Patterns of Hepatitis B Virus to Predict Hepatocellular Carcinoma With Deep Sequencing and Machine Learning.
Chen S; Zhang Z; Wang Y; Fang M; Zhou J; Li Y; Dai E; Feng Z; Wang H; Yang Z; Li Y; Huang X; Jia J; Li S; Huang C; Tong L; Xiao X; He Y; Duan Y; Zhu S; Gao C
J Infect Dis; 2021 Jun; 223(11):1887-1896. PubMed ID: 33049037
[TBL] [Abstract][Full Text] [Related]
39. Alpha-fetoprotein, protein induced by vitamin K absence or antagonist-II, lens culinaris agglutinin-reactive fraction of alpha-fetoprotein alone and in combination for early detection of hepatocellular carcinoma from nonalcoholic fatty liver disease: A multicenter analysis.
Guan MC; Ouyang W; Liu SY; Sun LY; Chen WY; Tong XM; Zhu H; Yang T
Hepatobiliary Pancreat Dis Int; 2022 Dec; 21(6):559-568. PubMed ID: 35643910
[TBL] [Abstract][Full Text] [Related]
40. Novel machine learning models outperform risk scores in predicting hepatocellular carcinoma in patients with chronic viral hepatitis.
Wong GL; Hui VW; Tan Q; Xu J; Lee HW; Yip TC; Yang B; Tse YK; Yin C; Lyu F; Lai JC; Lui GC; Chan HL; Yuen PC; Wong VW
JHEP Rep; 2022 Mar; 4(3):100441. PubMed ID: 35198928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
